Necuparanib, A Multitargeting Heparan Sulfate Mimetic, Targets Tumor and Stromal Compartments in Pancreatic Cancer

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Pancreatic cancer has a very low 5-year survival rate, necessitating new therapeutic strategies.
• Current treatments for pancreatic cancer are limited, highlighting the urgent need for novel drugs.

Purpose of the Study:

• To investigate the antitumor activity of necuparanib, a heparin-based mimetic, in pancreatic cancer models.
• To elucidate the molecular mechanisms underlying necuparanib's anti-cancer effects.

Main Methods:

• Utilized in vitro 3D culture models and in vivo animal models of pancreatic cancer.
• Performed proteomic analysis to identify proteins affected by necuparanib.
• Analyzed plasma samples from a Phase I/II clinical study of necuparanib in metastatic pancreatic cancer patients.

Main Results:

• Necuparanib inhibited pancreatic tumor cell proliferation and invasion in vitro.
• In vivo studies showed necuparanib extended survival and reduced metastasis.
• Proteomic analysis revealed necuparanib modulated proteins in key cancer pathways, including matrix metalloproteinases (MMPs).
• Necuparanib decreased MMP1 and increased tissue inhibitor of metalloproteinase 3 (TIMP3) levels, with reduced MMP activity observed.
• Clinical study confirmed increased TIMP3 plasma levels in patients treated with necuparanib plus standard of care.

Conclusions:

• Necuparanib demonstrates broad multitargeting therapeutic potential against pancreatic cancer.
• The drug exhibits significant in vitro and in vivo anti-invasive and antimetastatic activity.
• Necuparanib represents a promising novel therapeutic agent for pancreatic cancer treatment.